Drug manufacturer Novo Nordisk is giving 340B covered entities refunds for overcharges on two package sizes of its Tresiba FlexTouch insulin pen and on 10 milliliter vials of its Fiasp brand insulin.
The U.S. Health Resources and Services Administration (HRSA) posted the manufacturer’s notice to covered entities on July 23. The overcharges occurred from Q3 2018
through Q4 2018. Novo Nordisk is working with Apexus, the 340B prime vendor, to issue credits to entities’ wholesaler accounts.
Effective Jan. 1, Novo Nordisk stopped distributing 340B-purchased drugs to hospitals’ contract pharmacies under bill-to/ship-to arrangements. The Tresiba and Fiasp refunds it just announced are unrelated to its 340B contract pharmacy actions.